resiquimod has been researched along with mart-1 antigen in 2 studies
| Studies (resiquimod) | Trials (resiquimod) | Recent Studies (post-2010) (resiquimod) | Studies (mart-1 antigen) | Trials (mart-1 antigen) | Recent Studies (post-2010) (mart-1 antigen) |
|---|---|---|---|---|---|
| 465 | 14 | 318 | 1,241 | 99 | 446 |
| Protein | Taxonomy | resiquimod (IC50) | mart-1 antigen (IC50) |
|---|---|---|---|
| HLA class I histocompatibility antigen, A alpha chain | Homo sapiens (human) | 0.2624 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.2624 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.2624 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.2624 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.2624 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y | 1 |
| Allred, JB; Block, MS; Markovic, SN; Nevala, WK; Pang, YP; Strand, C | 1 |
1 trial(s) available for resiquimod and mart-1 antigen
| Article | Year |
|---|---|
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
Topics: Administration, Topical; Aged; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Cytokines; Female; Gene Products, gag; HLA-A2 Antigen; Humans; Imidazoles; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Pilot Projects; Skin Neoplasms | 2019 |
1 other study(ies) available for resiquimod and mart-1 antigen
| Article | Year |
|---|---|
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7 | 2014 |